Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Flow ⢠Elevated Leverage ⢠Improving Liquidity BMY offers strong cash generation, margins, and dividend support at moderate valuation, but high leverage and intangible exposure warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Modest uptrend ⢠Resistance rejection ⢠Balanced momentum Support Level: $66.00â$66.60 Resistance Level: $67.90â$68.10 BMY gained 3.2% over the last month and remains above its average, but failure to hold above $68.10 suggests consolidation between $66.00 support and $67.90â$68.10 resistance.
Sentiment & News
Key News Insights: ⢠Growth Portfolio ⢠Raised Guidance ⢠Patent Headwinds Bristol Myers Squibb's growth portfolio, improving guidance, value valuation, and Houston investment support upside, though Eliquis patent risk and generic pressure remain key headwinds.
AI Summary
BMY is transitioning from a patent-cliff value play to an execution-driven recovery: its growing portfolio is offsetting legacy erosion and supports the dividend, but upside now depends on new products scaling fast enough to outrun Revlimid, Eliquis and Opdivo declines amid high leverage.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |